arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Caris Life Sciences, Inc.

CAI

$22.74 ▲ +2.74 (+13.70%) at close

11 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Caris Life Sciences, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.4B

Dividend Yield —

Revenue Growth 78.8% ↘

Op. Margin 2.4% ↘

ROIC 0.4% ↘

FCF / Share $0.08

Trailing P/E —

Price / Book 10.8x

FCF Yield 0.4%

Debt / Equity 0.64

info Valuation on last close. End-of-day price, Aug 7, 2026.

11-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$216.17M

↑ +78.8% —

Net Income Profit after all expenses

$-510.00K

↑ +99.5% —

Operating Margin Operating profit as % of sales

2.4%

↓ -91.9% 44th

FCF / Share Free cash flow per share

$0.08

↓ -59.3% —

Long-Term Debt Long-term obligations

$381.07M

↑ +0.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Financial Health

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	78.8% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+885%)	125.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1468%)	113.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1317%)	81.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+916%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-213.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	99.5% Excellent Excellent Year-over-year change in net income	N/M	N/M	-8.5% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Operating Margin (%) (%)	2.4% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-84%)	30.2% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+101%)	15.1% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: At sector avg	-9.9% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-166%)	-47.9% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-420%)	-28.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-290%)	-59.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-499%)	-67.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-547%)	—	—	—
Effective Tax Rate (%) (%)	20.8% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	-0.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-102%)	28.0% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+133%)	11.2% Fair ↑ Fair Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-7%)	-39.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-430%)	-84.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-807%)	-28.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-337%)	-66.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-655%)	-66.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-651%)	—	—	—
FCF Margin (%) (%)	10.4% Fair ↓ Fair Declining Free cash flow as a percentage of revenue Optimal: > 10%	13.6% Fair ↑ Fair Improving Free cash flow as a percentage of revenue Optimal: > 10%	25.5% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	3.3% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-28.1% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-31.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-70.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	-44.18x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	2.27x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.33x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	0.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.3% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	3.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-2.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	2.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	1.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	2.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	2.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	0.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	7.9% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	3.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-10.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-0.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-101%)	14.2% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-5%)	5.1% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-66%)	-15.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-206%)	3.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-74%)	1.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-90%)	2.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-82%)	2.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-81%)	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	0.64x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+7%)	0.66x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+9%)	0.79x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+31%)	0.82x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+37%)	—	-0.15x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-125%)	—	—	—	—	—
Interest Coverage (x)	0.41x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	7.80x Good ↑ Good Improving Operating income divided by interest expense Optimal: > 5x	2.42x Caution ↑ Caution Improving Operating income divided by interest expense Optimal: > 5x	-0.94x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-4.54x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2.79x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-4.41x Weak Weak Operating income divided by interest expense Optimal: > 5x	-4.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-438.83M	$-417.82M	$-377.34M	$-345.52M	$-31.20M	$309.19M	—	—	—	—	—
Debt / EBITDA (x)	36.83x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	4.08x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	10.01x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-32.22x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-13.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.77	—	$0.77	$2.79	$3.39	—	$2.85	$2.83	—	—	—
Basic EPS, GAAP (USD)	$0.00	$1.61	$0.09	$-7.97	$-3.57	$-1.74	$-2.59	$-2.54	—	—	—
Free Cash Flow per Share (USD)	$0.08	—	$0.20	$0.09	$-0.96	—	$-2.00	—	—	—	—
Book Value per Share (USD)	$2.10	$2.04	$1.70	$1.61	$-72.98	$-68.45	$-68.51	$-66.71	—	—	—
Tangible Book Value per Share (USD)	$2.03	$1.97	$1.63	$1.54	$-72.98	$-68.98	$-68.51	$-66.71	—	—	—
Basic Weighted Avg Shares (shares)	282.56M	—	282.10M	64.92M	35.62M	—	35.64M	35.37M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$870.28M	$870.65M	$768.22M	$743.14M	—	$50.31M	—	—	—	—	—
LT Debt (USD)	$381.07M	$378.45M	$375.88M	$373.42M	—	$373.14M	—	—	—	—	—
Total Equity (USD)	$593.49M	$577.31M	$478.36M	$452.90M	$-2.60B	$-2.50B	$-2.44B	$-2.36B	$-2.27B	$-2.14B	$-1.70B

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$216.17M	$292.89M	$216.83M	$181.40M	$120.92M	$129.91M	$101.62M	$100.05M	—	—	—
Depreciation Expense (USD)	$5.07M	$4.29M	$4.90M	$6.40M	$7.04M	$9.07M	$10.50M	$11.60M	—	—	—
Net Income, GAAP (USD)	$-510.00K	$81.96M	$24.32M	$-71.79M	$-102.58M	$-36.95M	$-67.73M	$-66.19M	—	—	—
Operating Cash Flow (USD)	$32.88M	$44.78M	$62.42M	$7.29M	$-31.34M	$-38.92M	$-69.43M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 11 quarters

Caris Life Sciences, Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CAI with peers